Get the app
USHealthcare

Envista Holdings Corp (NVST)

US · Healthcare · Medical Instruments & Supplies

$23.69-5.13%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$730.5M
Revenue YoY
+7.1%
Net profit
$53.7M
Profit YoY
+103.4%
EPS
$0.41
EPS estimate
$0.33
Net margin
7.4%

EPS came in at 0.41 against a street estimate of 0.33 — a beat of 24.2%.

Key statistics

Market cap
$4.10B
P/E
44.1
Forward P/E
20.3
P/B
1.33
Book value
$19.16
EPS (TTM)
$0.58
52-week high
$30.42
52-week low
$18.77
50-day MA
$27.16
200-day MA
$25.44
Beta
0.86

Analyst view

Analysts rate Envista Holdings Corp a hold (3 buy, 10 hold, 1 sell out of 14) with an average price target of $30.79.

From the latest earnings call · 2026-08-05

CONFIDENT Envista delivered 5% core growth in Q2 with 28% EBITDA growth and 58% EPS growth. Raised full-year guidance across all metrics. Equipment & Consumables accelerating; VBP implementation expected in China second half. Q2 2026 All major geographies posted growth in Q2. China down year-to-date due to VBP compression; expected to grow moderately in second half post-VBP implementation. Analysts pressed heavily on China VBP timing, underlying growth rates, and margin drivers. Management reiterated VBP as net positive long-term based on implants VBP 1 precedent. Addressed concerns that H2 deceleration was conservative; confirmed 3.5% normalized ex adjustments. 2026-08-05…

Full summary in the app.

Shareholding

Insiders
0.59%
Institutions
120.86%

Largest institutional holders

FundStake
BlackRock Inc11.12%
Ariel Investments, LLC6.11%
Dimensional Fund Advisors, Inc.5.96%
Morgan Stanley - Brokerage Accounts5.47%
Vanguard Portfolio Management, LLC4.71%
Vanguard Capital Management, LLC4.56%
Franklin Templeton Inc4.29%
Gates Capital Management Inc3.46%

Recent filings & reports

DocumentDate
Board / officer change · Q3 2026
ENVISTA HOLDINGS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Paul Keel (President and CEO) base salary increased by $200,000: from $1.1 millio
2026-08-19
Quarterly report · Q3 2026
ENVISTA HOLDINGS CORPORATION – FORM 10-Q SUMMARY For Quarterly Period Ended July 3, 2026 --- HEADLINE NUMBERS • Sales (6 months): $1,436.0 million,
2026-08-05
Results announced · Q3 2026
ENVISTA HOLDINGS CORPORATION – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Sales: $730.5 million, up 7.1% vs. Q2 2025 ($682.1 million) • Cor
2026-08-05
Board / officer change · Q2 2026
ENVISTA HOLDINGS CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics or performance data disclosed in this filing • Document is a
2026-06-03
Shareholder vote results · Q2 2026
ENVISTA HOLDINGS CORPORATION – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held on May 19, 2026 • Total votes cast for director el
2026-05-21
Quarterly report · Q2 2026
ENVISTA HOLDINGS CORPORATION – Q1 2026 (10-Q) SUMMARY HEADLINE NUMBERS • Sales: $705.5 million (Q1 2026) vs. $616.9 million (Q1 2025) — +14.3% growt
2026-05-06
Proxy statement · Q4 2025
ENVISTA HOLDINGS CORPORATION – 2026 PROXY SUMMARY --- CEO COMPENSATION • Paul Keel (President and CEO since 2024) compensation figures not fully de
2026-04-07
Annual report FY2025
ENVISTA HOLDINGS CORPORATION – 2025 10-K SUMMARY HEADLINE NUMBERS • Total sales for fiscal year 2025: $2,719.5 million (vs. $2,510.6 million in 2024
2026-02-12

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Envista Holdings Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.